

Due to their enormous potential for advancing drug discovery, there continues to be an exponential growth in the use of single cell sequencing methods, with pharmaceutical companies continuing to invest in them. In addition, there is an ever-increasing amount of single cell datasets being generated and deposited in the public domain.

The availability of vast amounts of publicly available single cell datasets offers pharmaceutical companies the opportunity to expand the universe of experiments available to their scientists many fold. While many of these datasets are freely available, they come with hidden costs that hinder the ability of companies to exploit them to their maximum potential:

PROS

The availability of ever-increasing amounts of transcriptomic datasets in the public domain

Pharma companies can **increase** the number of single cell experiments available to its scientists **many fold** by combining with their private experiments

Most datasets are available at **no cost!**

CONS

No common standards exist for how single cell datasets are created, formatted, metadata captured (if at all) to be deposited in public sources

It is **difficult and time consuming** for pharma companies to fully exploit these valuable sources of data


80% effort is spent on curating/wrangling/integrating data versus only **20% on analysis**

- No common standards exist at present for publishing single cell datasets
- It is time consuming and laborious for pharmaceutical companies to find, download and curate single cell datasets into an accepted common format so they can then be analyzed collectively

February 25, 2022, Rancho launched Single Cell Data Science Consortium with 4 Charter Members. This multi-year effort will deliver harmonized single cell experiments more quickly and cost effectively.

BENEFITS OF MEMBERSHIP

- Cost sharing approach, with far superior ROI to what one company could achieve on its own. ROI will continue to grow as more Members join
- With its expertise in data curation, Rancho can scale the effort much faster and more cost effectively than a single company
- Ability to interact regularly with like-minded peers at other pharmaceutical companies, in a pre-competitive manner, to share common challenges they face in working with single cell datasets and how the field can be advanced together



CONSORTIUM MEMBERS



MEMBERSHIP IN THE SINGLE CELL DATA SCIENCE CONSORTIUM

New members are welcome to join the consortium, please email Services@RanchoBioSciences.com if you are interested in becoming a member.



www.RanchoBioSciences.com

T (760)-717-7881

E Services@RanchoBioSciences.com